In this study we have reported on a series of patients with endometrial carcinoma and atypical endometrial hyperplasia who were treated with GnRHa plus LNG-IUD/aromatase inhibitors. The gene discussed is CYP19A1; the disease is atypical endometrial hyperplasia.